Sotera Health Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased by 9.2% to $321 million, or 8% on a constant currency basis.

Net Income: GAAP net income was $54 million, equating to $0.19 per diluted share.

Adjusted EBITDA: Rose by 10% to $166 million, with an adjusted EBITDA margin of 51.6%, up 36 basis points year-over-year.

Adjusted EPS: Increased by 30% to $0.26 per diluted share.

Interest Expense: Reduced to $34 million, benefiting from term loan repricing and debt reduction.

Net Leverage Ratio: Improved to 3x, achieving the long-term target range of 2 to 3x.

2Strategic Updates and Business Highlights

Leadership Transition: Alton Shader assumed the role of CEO on May 26, 2026, succeeding Michael Petras, who remains Executive Chairman.

Business Performance:

Sterigenics: 8.6% revenue growth (7% constant currency), driven by favorable pricing and volume.

Nordion: 15.8% revenue growth (16.7% constant currency), attributed to increased volume and pricing.

Nelson Labs: 6.3% revenue growth (5.4% constant currency), with a focus on leveraging technical expertise to solve customer issues.

Leadership Changes: Riaz Bandali appointed as President of Nelson Labs following Joe Shrawder's retirement.

Customer Focus: Emphasis on enhancing customer partnerships and cross-business collaboration.

3Forward Guidance and Outlook

Revenue Growth: Full-year 2026 revenue expected to be between $1.236 billion and $1.254 billion, reflecting 5.25% to 6.75% constant currency growth.

Adjusted EBITDA Growth: Projected to be between $634 million and $643 million, representing 5.75% to 7.25% constant currency growth.

CapEx: Expected to be between $200 million and $225 million, with a significant step-up due to growth investments and facility enhancements.

Adjusted EPS Outlook: Revised to a range of $0.95 to $1.01 per diluted share.

4Bad News, Challenges, or Points of Concern

Inflationary Pressures: Ongoing standard inflation in labor and materials costs impacting margins, particularly in Nelson Labs.

Competitive Landscape: While competition remains stable, there are concerns regarding potential pricing pressures and market dynamics.

Litigation Risks: Ongoing litigation in Georgia and California, with potential impacts on future operations and financials.

5Notable Q&A Insights

Nelson Labs Performance: Growth attributed to both new projects and ongoing client relationships, with expectations for continued demand.

Sterigenics Volumes: Demand remains stable, with no significant changes in competition noted. A large customer is shifting from in-sourcing to outsourcing sterilization services.

X-ray Facility: Progressing well, with revenue expected to flow from the new facility starting in Q3 2026.

Capital Allocation: Focus on internal investments and potential M&A, with a strategic planning process underway to maximize growth. Overall, Sotera Health reported a strong quarter with solid growth across its business segments, a leadership transition, and an optimistic outlook for the remainder of 2026, despite facing some inflationary pressures and ongoing litigation challenges.